You are viewing the site in preview mode

Skip to main content

Advertisement

Table 5 Risk factors for 30-day patient mortality grouped by MRSA risk score

From: Application of a methicillin-resistant Staphylococcus aureus risk score for community-onset pneumonia patients and outcomes with initial treatment

  Adjusted Odds ratio (95 % confidence interval)
Risk score All (n = 80,330) 0–1 (n = 41,282) 2–5 (n = 37,975) 6–10 (n = 1,073)
MRSA therapy 1.22 (1.17-1.27) 1.47 (1.37-1.58) 1.05 (1.00-1.11) 0.57 (0.42-0.77)
Age (1-year increments) 1.05 (1.04-1.05) 1.05 (1.05-1.06) 1.04 (1.03-1.04) 1.05 (1.02-1.08)
Race 0.99 (0.94-1.05) 0.95 (0.86-1.06) 0.98 (0.91-1.05) 1.18 (0.85-1.64)
Hispanic ethnicity 0.85 (0.79-0.92) 0.84 (0.73-0.96) 0.86 (0.79-0.95) 0.79 (0.47-1.32)
Comorbid conditions
 Myocardial infarction 1.14 (1.06-1.23) 1.11 (0.94-1.30) 1.05 (0.97-1.14) 1.06 (0.74-1.51)
 Heart failure 1.16 (1.11-1.21) 1.07 (0.97-1.17) 1.11 (1.05-1.18) 1.16 (0.88-1.53)
 COPD 0.96 (0.91-1.00) 0.92 (0.85-1.00) 0.95 (0.89-1.01) 1.30 (0.96-1.77)
 Liver disease 1.79 (1.54-2.08) 1.34 (0.97-1.87) 1.80 (1.50-2.14) 3.46 (1.08-13.51)
 Renal disease 0.98 (0.93-1.04) 0.91 (0.81-1.02) 0.96 (0.90-1.03) 1.12 (0.83-1.53)
 Neoplastic disease 1.54 (1.47-1.60) 1.57 (1.46-1.69) 1.48 (1.40-1.56) 1.18 (0.87-1.59)
Medication use, by class
 Cardiovascular medications 0.72 (0.69-0.75) 0.60 (0.56-0.64) 0.78 (0.73-0.82) 0.91 (0.66-1.24)
 Anti-diabetic medications 0.92 (0.87-0.96) 0.78 (0.71-0.86) 0.95 (0.90-1.01) 0.95 (0.70-1.29)
 Inhaled corticosteroids 0.76 (0.72-0.81) 0.73 (0.65-0.81) 0.80 (0.74-0.86) 1.13 (0.77-1.65)
 Pulmonary medications 1.00 (0.94-1.05) 0.93 (0.85-1.03) 1.03 (0.97-1.11) 0.68 (0.48-0.97)
Vasopressors 1.81 (1.70-1.93) 3.00 (2.49-3.61) 1.66 (1.55-1.79) 1.52 (1.12-2.04)
Mechanical ventilation
 Invasive 1.08 (1.01-1.16) 2.48 (1.98-3.10) 1.02 (0.95-1.10) 0.92 (0.65-1.29)
 Noninvasive 1.16 (1.06-1.27) 2.03 (1.60-2.57) 1.03 (0.94-1.13) 1.22 (0.80-1.86)
Organ failure
 Respiratory 2.48 (2.34-2.63) 3.84 (3.45-4.29) 2.03 (1.90-2.18) 1.47 (1.06-2.04)
 Cardiovascular 1.91 (1.80-2.02) 1.90 (1.68-2.15) 1.81 (1.69-1.94) 1.36 (1.02-1.82)
 Neurological 1.53 (1.38-1.71) 1.64 (1.33-2.02) 1.40 (1.23-1.58) 1.92 (1.03-3.65)
 Renal 1.58 (1.51-1.66) 1.77 (1.62-1.94) 1.46 (1.38-1.55) 1.15 (0.87-1.51)
 Hematologic 1.65 (1.52-1.80) 1.97 (1.67-2.32) 1.53 (1.39-1.69) 1.18 (0.73-1.90)
 Hepatic 2.54 (2.08-3.11) 3.21 (2.05-5.00) 2.38 (1.90-2.99) 0.66 (0.20-2.16)
Antibiotic therapy
 GC-CAP therapy 0.67 (0.63-0.70) 0.60 (0.54-0.67) 0.73 (0.69-0.79) 0.73 (0.50-1.08)
 Pseudomonal therapy 1.25 (1.19-1.32) 1.68 (1.53-1.85) 1.05 (0.99-1.12) 0.76 (0.54-1.06)
 Atypical therapy 0.45 (0.43-0.48) 0.59 (0.53-0.66) 0.46 (0.43-0.49) 0.75 (0.52-1.08)
MRSA culture positivity 0.66 (0.59-0.74) 0.58 (0.45-0.73) 0.66 (0.58-0.75) 0.56 (0.31-0.99)
  1. Bold indicates statistical significance; MRSA Methicillin-resistant Staphylococcus aureus; Race was ordered as black versus nonblack; COPD Chronic obstructive pulmonary disease, GC-CAP Guideline-concordant community-acquired pneumonia